-
May 6: The Week in Cancer News
Adolescents and young adult cancer survivors at higher risk for dying from a new cancer diagnosis, and FDA grants full approval to Enhertu for metastatic HER2-postive breast cancer.
by Eric Fitzsimmons
-
April 29: The Week in Cancer News
FDA proposes ban on menthol cigarettes, and proton beam therapy on the rise but with growing racial disparity.
by Thomas Celona
-
April 22: The Week in Cancer News
Study finds a connection between bacteria and fast-growing prostate cancer, and researchers measure underrepresentation of Black patients in clinical trials.
by Kevin McLaughlin
-
April 15: The Week in Cancer News
Trial of ‘practice-changing’ immunotherapy yields positive results for lung cancer patients, and CAR T-cell therapy shows effectiveness in targeting certain solid tumors.
by Thomas Celona
-
April 8: The Week in Cancer News
CAR T-cell therapy approved for relapsed large B-cell lymphoma, and screening catches lung cancer earlier, although disparities persist.
by Kevin McLaughlin
-
April 1: The Week in Cancer News
Chemo brain may provide clues for long-haul COVID-19, and researchers analyze relationship between obesity and cancer.
by Marci A. Landsmann
-
March 25: The Week in Cancer News
FDA approves combination immunotherapy for treating melanoma, and screening tool improves pancreatic cancer detection.
by Kevin McLaughlin
-
March 18: The Week in Cancer News
Metastatic prostate cancer incidence rose after recommendation against routine screening, and FDA approves first PARP inhibitor for early-stage breast cancer for people with inherited BRCA mutations.
by Eric Fitzsimmons
-
March 11: The Week in Cancer News
FDA approves neoadjuvant immunotherapy treatment for lung cancer, and radiation might not be needed for low-risk thyroid cancer.
by Kevin McLaughlin
-
March 4: The Week in Cancer News
Study finds lower rates of screening-related breast cancer overdiagnosis and children with cancer in Ukraine continue treatment in hospital’s basement.
by Marci A. Landsmann
Cancer Talk
Treating HER2-ultralow Breast Cancer
FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
Lessons Learned as a Caregiver and PatientAfter caring for her husband during his cancer treatment, Miriam Díaz-Gilbert was prepared to face her DCIS diagnosis.
by Miriam Díaz-Gilbert
Screening Options for People With Dense BreastsReports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore